Расширенный поиск

Хроническая обструктивная болезнь легких: особенности у женщин

Полный текст:

Об авторах

С.И. Овчаренко
ГОУ ВПО "Московская медиуинская академия им. И.М.Сеченова"

В.А. Капустина
ГОУ ВПО "Московская медицинская академия им. И.М.Сеченова"

Список литературы

1. Mannino D.M., Buist A.S. Global burden of COPD: risk factors, prevalence, and future Trends. Lancet 2007; 370: 765-773.

2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2007 (www.

3. Celli B.R., MacNee W., Agusti A.G. et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932-946.

4. A report of the task force on the NIH's women's health research agenda for the twentyfirst century. Bethesda, MD: National Institutes of Health; 1999. NIH Publication No. 99-4385.

5. Чучалин А.Г. Белая книга. Пульмонология. Россия 2003. М.; 2003.


7. Soriano J.R., Maier W.C., Egger P. et al. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 2000; 55: 789-794.

8. Feenstra T.L., van Genugten M.L., Hoogenveen R.T. et al. The impact of ageing and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am. J. Respir. Crit. Care Med. 2001; 164: 590-596.

9. Miller J.D., Foster T., Boulanger L. et al. Direct costs of COPD in the U.S.: an analysis of Medical Expenditure Panel Survey (MEPS) data. COPD 2005; 2: 311-318.

10. Jemal A., Ward E., Hao Y., Thun M. Trends in the leading causes of death in the United States, 1970-2002. J. A. M. A. 2005; 294: 1255-1259.

11. Brett K.M., Hayes S.G.Women's health and mortality chartbook. Washington, DC: DHHS Office on Women's Health; 2004.

12. Mathers D.M., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3: e442.

13. Chapman K.R. Chronic obstructive pulmonary disease: are women more susceptible than men? Clin. Chest Med. 2004; 25: 331-341.

14. Mannino D.M., Homa D.M., Akinbami L.J. et al. Chronic obstructive pulmonary disease surveillance: United States, 1971-2000. MMWR Surveill. Summ. 2002; 51: 1-16.

15. Vestbo J. Epidemiology. In: Voelkel N.F., MacNee W., eds. Chronic obstructive lung disease. Hamilton, Canada: BC Decker Inc.; 2002. 41-55.

16. Esson K., Leeder S.R. The millennium development goals and tobacco control: an opportunity for global partnership. Geneva: World Health Organization; 2004.

17. World Health Organization. Gender, health, and tobacco. Geneva: World Health Organization; 2003.

18. Ernster V. Women and the tobacco epidemic: challenges for the 21st century. Geneva: World Health Organization; 2001.

19. Mackay J., Amos A. Women and tobacco. Respirology 2003; 8: 123-130.

20. The European tobacco control report 2007. Jeneva: World Health Organization, 2007; 153.

21. Герасименко Н.Ф., Заридзе Д.Г., Сахарова Г.М. Здоровье или табак. М.: Форум "Здоровье или табак"; 2007.

22. Mollerup S., Ryberg D., Hewer A. et al. Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res. 1999; 59: 3317-3320.

23. Han W., Pentecost B.T., Pietropaolo R.L. et al. Estrogen receptor alpha increases basal and cigarette smoke extract-induced expression of CYP1A1 and CYP1B1, but not GSTP1, in normal human bronchial epithelial cells. Mol. Carcinog. 2005; 44: 202-211.

24. Benowitz N.L., Lessov-Schlaggar C.N., Swan G.E., Jacob P. III. Female sex and oral contraceptive use accelerate nicotine metabolism. Clin. Pharmacol. Ther. 2006; 79: 480-488.

25. Xu X., Li B., Wang L. Gender difference in smoking effects on adult pulmonary function. Eur. Respir. J. 1994; 7: 477-483.

26. Xu X., Weiss S.T., Rijcken B., Shouten J.P. Smoking, changes in smoking habits, and rates of decline in FEV1: new insight into gender differences. Eur. Respir. J. 1994; 7: 1056-1061.

27. Prescott E., Bjerg A.M., Andersen P.K. et al. Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal study. Eur. Respir. J. 1997; 10 (4): 822-827.

28. Carter R., Nicotra B., Huber G. Differing effects of airway obstruction on physical work capacity and ventilation in men and women with COPD. Chest 1994; 106 (6): 1730-1739.

29. Camilli A.E., Burrows B., Knudson R.J. et al. Longitudinal changes in forced expiratory volume in one second in adults. Am. Rev. Respir. Dis. 1987; 135: 794-799.

30. Peat J.K., Woolcock A.J., Cullen K. Decline of lung function and development of chronic airflow limitation: a longitudinal study of smokers and nonsmokers in Busselton. Western Australia. Thorax 1990; 45: 32-37.

31. Anthonisen N.R., Connet J.E., Murray R.P. for the Lung Health Study Research Group. Smoking and lung function of lung health study participants after 11 years. Am. J. Respir. Crit. Care Med. 2002; 166: 675-679.

32. de Torres J., Campo A., Casanova C. et al. Gender and chronic obstructive pulmonary disease in highrisk smokers. Respiration 2006; 73: 306-310.

33. Birring S.S., Brightling C.E., Bradding P. et al. Clinical, radiological, and induced sputum features of chronic obstructive pulmonary disease in nonsmokers. Am. J. Respir. Crit. Care Med. 2002; 166: 1078-1083.

34. He J., Gu D., Wu X. et al. Major causes of death among men and women in China. N. Engl. J. Med. 2005; 353: 1124-1134.

35. Ramirez-Venegas A., Sansores R.H., Perez-Padilla R. et al. Survival of patients with chronic obstructive pulmonary disease due to biomass smoke and tobacco. Am. J. Respir. Crit. Care Med. 2006; 173: 393-397.

36. Dockery D.W., Pope C.A., Xu X. et al. An association between air pollution and mortality in six US cities. N. EngI. J. Mod. 1993; 329: 1753-1759.

37. Tao X., Hong C.J., Yu S. et al. Priority among air pollution factors for preventing chronic obstructive pulmonary disease in Shanghai. Sci. Total Environ. 1992; 127: 57-67.

38. Pandey M.R. Domestic smoke pollution and chronic bronchitis in a rural community of the Hill Region of Nepal. Thorax 1984; 39: 337-339.

39. Amoli K. Bronchopulmonary disease in Iranian housewives chronically exposed to indoor smoke. Eur. Respir. J. 1998; 11: 659-663.

40. Dossing M., Khan J., al-Rabiah F. Risk factors for chronic obstructive lung disease in Saudi Arabia. Respir. Med. 1994; 88: 519-522.

41. Perez-Padilla R., Regalado U., Vedal S. et al. Exposure to biomass smoke and chronic airway disease in Mexican women. Am. J. Respir. Crit. Care Med. 1996; 154: 701-706.

42. Gan W.Q., Man S.F., Postma D.S. et al. Female smokers beyond the perimenopausal period are at increased risk of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir. Res. 2006; 7: 52.

43. Kanner R.E., Connett J.E., Altose M.D. et al. Gender differ ence in airway hyperresponsiveness in smokers with mild COPD: the Lung Health Study. Am. J. Respir. Crit. Care Med. 1994; 150: 956-961.

44. Paoletti P., Carrozzi L., Viegi G. et al. Distribution of bronchial responsiveness in a general population: effect of sex, age, smoking, and level of pulmonary function. Am. J. Respir. Crit. Care Med. 1995; 151: 1770-1777.

45. Rijken B., Schouten J.P., Xu X. et al. Airway hyperresponsiveness to hystamine is associated with accelerated decline of FEV1. Am. J. Respir. Crit. Care Med. 1995; 151: 1377-1382.

46. Martinez F.J., Curtis J.L., Sciurba F. et al. Sex differences in severe pulmonary emphysema. Am. J. Respir. Crit. Care Med. 2007; 176: 243-252.

47. Becklake M.R., Kauffmann F. Gender differences in airway behaviour over a human life span. Thorax 1999; 54: 1119-1138.

48. Kelly R.W., Illingworth P., Baldie G. et al. Progesteron control of interleukin-8 production in endometrium and choriodecidual cells underlines the role of the neutrophil in menstruation and parturition. Hum. Reprod. 1994; 9: 253-258.

49. Saetta M., Turato G., Maestrelli P. et al. Cellular and structural bases of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 1304-1309.

50. Kauffmann T., Becklake M.R. Sex and gender. Eur. Respir. Mon. 2000; 15: 288-304.

51. Lee P., Gildea T.R., Stoller J.K. Emphysema in nonsmokers: alpha-1-antitrypsin deficiency and other causes. Cleveland Clin. J. Med. 2002; 69: 928-946.

52. Silverman E.K., Weiss S.T., Drazen J.M. et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease: risk to relatives for airflow obstruction and chronic bronchitis. Am. J. Respir. Crit. Care Med. 1998; 157: 1770-1778.

53. Silverman E.K., Weiss S.T., Drazen J.M. et al. Gender-related differences in severe, early-onset chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 162: 2152-2158.

54. Wilson D.O., Rogers R.M., Wright E.C. et al. Body weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. Am. Rev. Respir. Dis. 1989; 139: 1435-1438.

55. Varkey A. Cronic obstructive pulmonary disease in women: exploring gender differences. Curr. Opin. Pulm. Med. 2004; 10: 98-103.

56. Torday J.S., Nielsen H.C. The sex difference in fetal lung surfactant production. Exp. Lung Res. 1987; 1: 1-19.

57. Fleisher B., Kulovich M.V., Hallman M., Gluck L. Lung profile: sex differences in normal pregnancy. Obstetr. and Gynecol. 1985; 66: 327-330.

58. Thurlbeck W.M. Postnatal human lung growth. Thorax 1982; 37: 564-571.

59. Quanjer P.H., Borsboom G.J., Brunekreff B. et al. Spirometric reference values for white European children and adolescents: Polgar revisited. Pediatr. Pulmonol. 1995; 19: 135-142.

60. Clausen J.L., Coates A.L., Quanjer P.H. Measurement of lung volumes in humans: review and recommendations from an ATS / ERS workshop. Eur. Respir. J. 1997; 10: 1205-1206.

61. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am. Rev. Respir. Dis. 1991; 144: 1202-1218.

62. Chapman K.R., Tachkin D.P., Pye D.J. Gender bias in the diagnosis of COPD. Chest 2001; 119: 1691-1695.

63. Anthonisen N.R., Wooldrage K., Manfreda J. Use of spirometry and respiratory drugs in Manitobans over 35 years of age with obstructive lung diseases. Can. Respir. J. 2005; 12: 69-74.

64. Watson L., Vestbo J., Postma D.S. et al. Gender differenses in the management and experience of chronic obstructive pulmonary disease. Respir. Med. 2004; 98: 1207-1203.

65. Camp P.G., Goring S.M. Gender and the diagnosis, management, and surveillance of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2007; 4: 686-691.

66. de Torres J.P., Casanova C., Hernandez C. et al. Gender and COPD in patients attending a pulmonary clinic. Chest 2005; 128: 2012-2016.

67. Di Marco F., Verga M., Reggente M. et al. Anxiety and depression in COPD patients: the roles of gender and disease severity. Respir. Med. 2006; 100: 1767-1774.

68. Watson L., Vonk J.M., Lofdahl C.G. et al. Predictors of lung function and its decline in mild to moderate COPD in association with gender: results from the EUROSCOP study. Respir. Med. 2006; 100: 746-753.

69. Cydulka R.K., Rowe B.H., Clark S. et al. Gender differences in emergency department patients with chronic obstructive pulmonary disease exacerbations. Acad. Emerg. Med. 2005; 12: 1173-1179.

70. Gift A.G., Shepard C.E. Fatigue and other symptoms in patients with chronic obstructive pulmonary disease: do women and men differ? J. Obstetr. Gynecol. Neonat. Nurs. 1999: 28: 201-208.

71. Katzura H., Yamada K., Wakagayashi R., Kida K. Genderassociated differences in dyspnea and health-related quality of life in patients with chronic obstructive pulmonary disease. Respirology 2007; 12: 427-432.

72. Low G., Gutman G. Examining the role of gender in health-related quality of life: perceptions of older adults with chronic obstructive pulmonary disease. J. Gerontol. Nurs. 2006; 21: 42-49.

73. Hesselink A.E., van der Windt P.A., Penninx B.W. et al. What predicts change in pulmonary function and quality of life in asthma or COPD? J. Asthma 2006; 43: 513-519.

74. Stahl E., Lindberg A., Jansson S.A. et al. Healthrelated quality of life is related to COPD severity. Hlth Qual. Life Outcomes 2005; 3: 56.

75. Renkema T.E., Schouten J.P., Koeter G.H., Postma D.S. Effects of long-term treatment with corticosteroids in COPD. Chest 1996; 109: 1156-1162.

76. Lee T.A., Weiss K.B. Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 169: 855-859.

77. Katsura H., Kida K. A comparison of bone mineral density in elderly female patients with COPD and bronchial asthma. Chest 2002; 122: 1949-1955.

78. Чучалин А.Г. (ред.). Хроническая обструктивная болезнь легких. (Федеральная программа): Практическое руководство для врачей. 2-е изд. М.; 2004.

79. Krzyzanowski M., Robbins D.R., Lebowitz M.D. Smoking cessation and changes in respiratory symptoms in two populations followed for 13 years. Int. J. Epidemiol. 1993; 22: 666-673.

80. Anthonisen N., Connet J., Kiley J. et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. J. A. M. A. 1994; 272: 1497-1505.

81. Scanlon P.D., Connett J.E., Waller L.A. et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am. J. Respir. Crit. Care Med. 2000; 161: 381-390.

82. Scharf D., Shiffman S. Are there gender differences in smoking cessation, with and without bupropion? Pooled- and meta-analysis of clinical trials of bupropion SR. Addiction. 2004; 99: 1462-1469.

83. Gritz E.R., Nielsen I.R., Brooks L.A. Smoking cessation and gender: the influence of physiological, psychological, and behavioral factors. J. Am. Med. Wom. Assoc. 1996; 51: 35-42.

84. Bjornson W., Rand C., Connett J.E. et al. Gender differences in smoking cessation after 3 years in the Lung Health Study. Am. J. Publ. Hlth 1995; 85: 223-230.

85. Panday S., Reddy S.P., Ruiter R. et al. Nicotine dependence and withdrawal symptoms among occasional smokers. J. Adolesc. Hlth 2007; 40: 144-150.

86. O'Hara P., Connett J.E., Lee W.W. et al. Early and late weight gain following smoking cessation in the Lung Health Study. Am. J. Epidemiol. 1998; 148 (9): 821-830.

87. Wise R.A., Enright P.L., Connett J.E. et al. Effect of weight gain on pulmonary function after smoking cessation in the Lung Health Study. Am. J. Respir. Crit. Care Med. 1998; 157 (3): 866-872.

88. Dales R.E., Mehdizadeh A., Aaron S.D. et al. Sex differences in the clinical presentation and management of airflow obstruction. Eur. Respir. J. 2006; 28: 319-322.

89. Ленней Дж., Иннс Дж.А., Кромптон Дж.К. Неправильное использование ингаляторов: оценка ингаляционной техники и предпочтений пациентов при сравнении семи различных ингаляционных устройств. Пульмонология 2005; 4: 80-84.

90. Goodman D.E., Israel E., Rosenberg M. et al. The influence of age, diagnosis and gender on proper use of metered dose inhalers. Am. J. Respir. Crit. Care Med. 1994; 150: 1256-1261.

91. Vestbo J., Soriano J.B., Anderson J.A. et al. Gender does not influence the response to the combination of salmeterol and fluticasone proprionate in COPD. Respir. Med. 2004; 98: 1045-1050.

92. O'Donnell D.E., Fluge T., Gerken F. et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur. Respir. J. 2004; 23: 832-840.

93. Convery R.P., Leitch D.N., Bromly C. et al. Effect of inhaled fluticasone propionate on airway responsiveness in treatment-naive individuals-a lesser benefit in females. Eur. Respir. J. 2000; 15: 19-24.

94. Decramer M., Celli B., Tashkin D.P. et al. Clinical trial design considerations in assessing longterm functional impacts of tiotropium in COPD: The UPLIFT trial. COPD 2004; 1: 303-312.

95. Tashkin D.P., Celli B., Senn S. et al. for the UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543-1554.

96. Cooper J.D., Trulock E.P., Triantafillou A.N. et al. Bilateral pneumonectomy (volume reduction) for chronic obstructive pulmonary disease. J. Thorac. Cardiovasc. Surg. 1995; 109: 106-119.

97. National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung volume reduction surgery. N. Engl. J. Med. 2001; 345: 1075-1082.

98. Haggerty M.C., Stockdale-Woolley R., Zuwallack R. Functional status in pulmonary rehabilitation participants. J. Cardiopulm. Rehabil. 1999; 19: 35-42.

99. Foy C.G., Rejeski W.J., Berry M.J. et al. Gender moderates the effects of exercise therapy on health-related quality of life among COPD patients. Chest 2001; 119: 70-76.

Для цитирования:

Овчаренко С., Капустина В. Хроническая обструктивная болезнь легких: особенности у женщин . Пульмонология. 2009;(2):102-112.

Просмотров: 72

ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)